Letrozole Monotherapy. NCCP National SACT Regimen. HSE.

Regulatory approval published by the Health Service Executive.

Citation

Letrozole Monotherapy, 2026, version number 4, NCCP National SACT Regimen, NCCP, viewed 26/03/2026, https://healthservice.hse.ie/documents/6817/371_Letrozole_.pdf

Regulatory approvals

Approved indications from this document for cancer drugs containing at least one biomarker.

Indication	Statements
Adjuvant treatment of postmenopausal women with hormone receptor positive invasive early breast cancer.	3
Neo-adjuvant treatment of postmenopausal women with hormone receptor positive breast cancer.	3
Extended adjuvant treatment of hormone-dependent-invasive breast cancer in postmenopausal women who have received prior adjuvant endocrine therapy for 5 years.	3

Therapeutic response

Precision oncology relationships for therapeutic response derived from this document.

Organization(s)	Biomarker(s)	Cancer type	Therapy(ies)
HSE (3)	ER positive, PR positive	Invasive Breast Carcinoma	Letrozole
HSE (3)	ER positive	Invasive Breast Carcinoma	Letrozole
HSE (3)	PR positive	Invasive Breast Carcinoma	Letrozole